Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck reports profit fall

Danish drugs manufacturer Lundbeck has posted a 1.6 per cent fall in first-quarter net profit to DKK930m (€124.7m)

Danish drugs manufacturer Lundbeck has posted a 1.6 per cent fall in first-quarter net profit to DKK930m (€124.7m).

The company's revenue increased by 7 per cent to DKK4.1bn (€550m) in the first quarter, however, driven by a positive development of key products: antidepressant Cipralex (escitalopram), Alzheimer's treatment Ebixa (memantine) and Parkinson's treatment Azilect (rasagiline). Lundbeck said the products generated sales growth in the quarter, of 6 per cent, 12 per cent and 15 per cent respectively.

Ulf Wiinberg, chief executive, said: "It has been a good first quarter and several positive pipeline events have improved our long-term outlook."

The company still expects to make full-year sales of up to DKK15.8bn (€2.2bn). Earnings before interest and tax, depreciation and amortisation (EBITDA) is still expected to be up to DKK4.6bn (€616m).

5th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...